Open AccessCOVID-19 Vaccination Strategy in Germany
Author(s) -
M. Pfeiffer-Ruiz,
Valerie E. Schröder
Publication year - 2021
Publication title -
clinical social work journal
Language(s) - English
Resource type - Journals
eISSN - 2222-386X
pISSN - 2076-9741
DOI - 10.22359/cswhi_12_2_05
Subject(s) - covid-19 , vaccination , economic shortage , german , european union , relevance (law) , population , medicine , political science , virology , business , environmental health , outbreak , geography , economic policy , law , disease , pathology , linguistics , philosophy , archaeology , government (linguistics) , infectious disease (medical specialty)
Vaccines are needed to reduce the mortality and economic damage caused by COVID-19. To date there are three approved vaccines in the European Union created by BioNTech/Pfizer, Moderna and AstraZeneca, but due to the high demand globally there are still shortages, forcing governments to create strategies to immunize their population prioritizing their citizens according to their risk evaluation and their systemic relevance. This review specifies on the German vaccination strategy.